PMID- 29140774
OWN - NLM
STAT- In-Data-Review
LR  - 20180217
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 36
IP  - 1
DP  - 2018 Jan 1
TI  - Anal Cancer Risk Among People With HIV Infection in the United States.
PG  - 68-75
LID - 10.1200/JCO.2017.74.9291 [doi]
AB  - Purpose People with HIV infection have an elevated risk of anal cancer. However, 
      recent calendar trends are incompletely described, and which population subgroups
      might benefit from cancer screening is unknown. Methods We used linked data from 
      HIV and cancer registries in nine US areas (1996 to 2012). We calculated
      standardized incidence ratios to compare anal cancer incidence in people with HIV
      infection with the general population, used Poisson regression to evaluate anal
      cancer incidence among subgroups of people with HIV and to assess temporal
      trends, and estimated the cumulative incidence of anal cancer to measure absolute
      risk. Results Among 447,953 people with HIV infection, anal cancer incidence was 
      much higher than in the general population (standardized incidence ratio, 19.1;
      95% CI, 18.1 to 20.0). Anal cancer incidence was highest among men who have sex
      with men (MSM), increased with age, and was higher in people with AIDS than in
      those without AIDS (ie, HIV only; adjusted incidence rate ratio, 3.82; 95% CI,
      3.27 to 4.46). Incidence among people with HIV increased steeply during 1996 to
      2000 (annual percentage change, 32.8%; 95% CI, -1.0% to 78.2%), reached a plateau
      during 2001 to 2008, and declined during 2008 to 2012 (annual percentage change, 
      -7.2%; 95% CI, -14.4% to 0.6%). Cumulative incidence after a 5-year period was
      high for MSM with HIV only age 45 to 59 or >/= 60 years (0.32% to 0.33%) and MSM 
      with AIDS age 30 to 44, 45 to 59, or >/= 60 years (0.29% to 0.65%). Conclusion
      Anal cancer incidence is markedly elevated among people with HIV infection,
      especially in MSM, older individuals, and people with AIDS. Recent declines may
      reflect delayed benefits of HIV treatment. Groups with high cumulative incidence 
      of anal cancer may benefit from screening.
FAU - Colon-Lopez, Vivian
AU  - Colon-Lopez V
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Shiels, Meredith S
AU  - Shiels MS
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Machin, Mark
AU  - Machin M
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Ortiz, Ana P
AU  - Ortiz AP
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Strickler, Howard
AU  - Strickler H
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Castle, Philip E
AU  - Castle PE
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Pfeiffer, Ruth M
AU  - Pfeiffer RM
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
FAU - Engels, Eric A
AU  - Engels EA
AD  - Vivian Colon-Lopez, Mark Machin, and Ana P. Ortiz, University of Puerto Rico, San
      Juan, PR; Meredith S. Shiels, Ruth M. Pfeiffer, and Eric A. Engels, National
      Cancer Institute, Bethesda, MD; and Howard Strickler and Philip E. Castle, Albert
      Einstein College of Medicine, Bronx, NY.
LA  - eng
GR  - U58 DP003931/DP/NCCDPHP CDC HHS/United States
GR  - U62 PS004011/PS/NCHHSTP CDC HHS/United States
GR  - HHSN261201300019C/CA/NCI NIH HHS/United States
GR  - U58 DP003919/DP/NCCDPHP CDC HHS/United States
GR  - U58 DP003875/DP/NCCDPHP CDC HHS/United States
GR  - U58 DP003879/DP/NCCDPHP CDC HHS/United States
GR  - U58 DP003868/DP/NCCDPHP CDC HHS/United States
GR  - HHSN261201300021C/CA/NCI NIH HHS/United States
GR  - U58 DP003921/DP/NCCDPHP CDC HHS/United States
GR  - U62 PS001005/PS/NCHHSTP CDC HHS/United States
GR  - U62 PS004001/PS/NCHHSTP CDC HHS/United States
GR  - U58 DP000824/DP/NCCDPHP CDC HHS/United States
PT  - Journal Article
DEP - 20171115
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
PMC - PMC5791846
EDAT- 2017/11/16 06:00
MHDA- 2017/11/16 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/11/16 06:00 [medline]
PHST- 2017/11/16 06:00 [entrez]
AID - 10.1200/JCO.2017.74.9291 [doi]
PST - ppublish
SO  - J Clin Oncol. 2018 Jan 1;36(1):68-75. doi: 10.1200/JCO.2017.74.9291. Epub 2017
      Nov 15.